Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Amy E. DeZern, MD, Anthony Sung, MD, Sharon Kim, MD, Hua-Ling Tsai, MS, Jeanne Kowalski, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Steven D. Gore, M.D., Ephraim Fuchs, MD, Michael A McDevitt, MD, PhD, Leo Luznik, MD, Richard J. Jones, MD, Mark J. Levis, MD, PhD

Blood (2010) 116 (21): 2172.

https://doi.org/10.1182/blood.V116.21.2172.2172

Published: 2010

Journal Articles

Critical Role of CD4+Foxp3+ T Cells In Gvhd Prevention with High-Dose Posttransplant Cyclophosphamide (Cy).

Sudipto Ganguly, PhD, Ephraim Fuchs, MD, Vedran Radojcic, MD, Leo Luznik, MD

Blood (2010) 116 (21): 3749.

https://doi.org/10.1182/blood.V116.21.3749.3749

Published: 2010

Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA

Blood (2010) 116 (21): 2362.

https://doi.org/10.1182/blood.V116.21.2362.2362

Published: 2010

Journal Articles

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Paul O’Donnell, MD, PhD, Leo Luznik, MD, Heather Symons, MD, Richard Jones, MD, Ted Gooley, PhD, Elizabeth Harrington, MSN, Sandra Warnock, Brenda Sandmaier, MD, Rainer Storb, MD, Ephraim Fuchs, MD

Blood (2006) 108 (11): 3135.

https://doi.org/10.1182/blood.V108.11.3135.3135

Published: 2006

NARROW

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Critical Role of CD4+Foxp3+ T Cells In Gvhd Prevention with High-Dose Posttransplant Cyclophosphamide (Cy).

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Email alerts

ASH Publications

American Society of Hematology

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

Critical Role of CD4+Foxp3+ T Cells In Gvhd Prevention with High-Dose Posttransplant Cyclophosphamide (Cy).

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only